This study assessed these prognostic differences.<h4>Methods</h4>We retrospectively analysed 989 patients with HR-positive, and HER2-negative BC who underwent surgery between January 2017 and August 2019 at our institution. The gene discussed is ERBB2; the disease is breast cancer.